A	a	O	O	O	O
Phase	phase	O	O	O	O
II	ii	O	O	O	O
trial	trial	O	O	O	O
of	of	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
WR-2721	wr-2721	O	O	OTHERS	I
(	(	O	O	O	O
amifostine	amifostine	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
for	for	O	O	O	O
metastatic	metastatic	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
:	:	O	O	O	O
an	an	O	O	O	O
Eastern	eastern	O	O	O	O
Cooperative	cooperative	O	O	O	O
Oncology	oncology	O	O	O	O
Group	group	O	O	O	O
Study	study	O	O	O	O
(E8188).BACKGROUND	(e8188).background	O	O	O	O
:	:	O	O	O	O
Cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
has	has	O	O	O	O
minimal	minimal	O	O	O	O
antitumor	antitumor	O	O	O	O
activity	activity	O	O	O	O
when	when	O	O	O	O
used	used	O	O	O	O
as	as	O	O	O	O
second-	second-	O	O	O	O
or	or	O	O	O	O
third-line	third-line	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
metastatic	metastatic	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Older	older	O	O	O	O
reports	reports	O	O	O	O
suggest	suggest	O	O	O	O
an	an	O	O	O	O
objective	objective	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
8	8	O	O	O	O
%	%	O	O	O	O
when	when	O	O	O	O
60	60	O	O	O	O
-	-	O	O	O	O
120	120	O	O	O	O
mg/m2	mg/m2	O	O	O	O
of	of	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
administered	administered	O	O	O	O
every	every	O	O	O	O
3	3	O	O	O	O
-	-	O	O	O	O
4	4	O	O	O	O
weeks	weeks	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
a	a	O	O	O	O
dose-response	dose-response	O	O	O	O
effect	effect	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
observed	observed	O	O	O	O
with	with	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
dose-limiting	dose-limiting	O	O	O	O
toxicities	toxicities	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
e.g.	e.g.	O	O	O	O
,	,	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
ototoxicity	ototoxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
)	)	O	O	O	O
have	have	O	O	O	O
limited	limited	O	O	O	O
its	its	O	O	O	O
use	use	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

WR-2721	wr-2721	O	O	OTHERS	I
or	or	O	O	O	O
amifostine	amifostine	CHEMICALS	O	OTHERS	I
initially	initially	O	O	O	O
was	was	O	O	O	O
developed	developed	O	O	O	O
to	to	O	O	O	O
protect	protect	O	O	O	O
military	military	O	O	O	O
personnel	personnel	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
event	event	O	O	O	O
of	of	O	O	O	O
nuclear	nuclear	O	O	O	O
war	war	O	O	O	O
.	.	O	O	O	O

Amifostine	amifostine	CHEMICALS	O	OTHERS	I
subsequently	subsequently	O	O	O	O
was	was	O	O	O	O
shown	shown	O	O	O	O
to	to	O	O	O	O
protect	protect	O	O	O	O
normal	normal	O	O	O	O
tissues	tissues	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
toxic	toxic	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
alkylating	alkylating	CHEMICALS	O	OTHERS	I
agents	agents	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
without	without	O	O	O	O
decreasing	decreasing	O	O	O	O
the	the	O	O	O	O
antitumor	antitumor	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
.	.	O	O	O	O

Early	early	O	O	O	O
trials	trials	O	O	O	O
of	of	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
amifostine	amifostine	CHEMICALS	O	OTHERS	I
also	also	O	O	O	O
suggested	suggested	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
and	and	O	O	O	O
severity	severity	O	O	O	O
of	of	O	O	O	O
cisplatin-induced	cisplatin-induced	O	O	O	O
nephrotoxicity	nephrotoxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
ototoxicity	ototoxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
neuropathy	neuropathy	O	DISEASE	OTHERS	I
were	were	O	O	O	O
reduced	reduced	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
A	a	O	O	O	O
Phase	phase	O	O	O	O
II	ii	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
amifostine	amifostine	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
conducted	conducted	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
progressive	progressive	O	O	O	O
metastatic	metastatic	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
who	who	O	O	O	O
had	had	O	O	O	O
received	received	O	O	O	O
one	one	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
one	one	O	O	O	O
,	,	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
regimen	regimen	O	O	O	O
for	for	O	O	O	O
metastatic	metastatic	O	O	O	O
disease	disease	O	O	O	O
.	.	O	O	O	O

Patients	patients	O	O	O	O
received	received	O	O	O	O
amifostine	amifostine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
910	910	O	O	O	O
mg/m2	mg/m2	O	O	O	O
intravenously	intravenously	O	O	O	O
over	over	O	O	O	O
15	15	O	O	O	O
minutes	minutes	O	O	O	O
.	.	O	O	O	O

After	after	O	O	O	O
completion	completion	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
amifostine	amifostine	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
,	,	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
120	120	O	O	O	O
mg/m2	mg/m2	O	O	O	O
was	was	O	O	O	O
administered	administered	O	O	O	O
over	over	O	O	O	O
30	30	O	O	O	O
minutes	minutes	O	O	O	O
.	.	O	O	O	O

Intravenous	intravenous	O	O	O	O
hydration	hydration	O	O	O	O
and	and	O	O	O	O
mannitol	mannitol	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
administered	administered	O	O	O	O
before	before	O	O	O	O
and	and	O	O	O	O
after	after	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Treatment	treatment	O	O	O	O
was	was	O	O	O	O
administered	administered	O	O	O	O
every	every	O	O	O	O
3	3	O	O	O	O
weeks	weeks	O	O	O	O
until	until	O	O	O	O
disease	disease	O	DISEASE	OTHERS	I
progression	progression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Forty-four	forty-four	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
enrolled	enrolled	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
which	which	O	O	O	O
7	7	O	O	O	O
(	(	O	O	O	O
16	16	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
were	were	O	O	O	O
ineligible	ineligible	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
median	median	O	O	O	O
of	of	O	O	O	O
2	2	O	O	O	O
cycles	cycles	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
was	was	O	O	O	O
administered	administered	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
37	37	O	O	O	O
eligible	eligible	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Six	six	O	O	O	O
partial	partial	O	O	O	O
responses	responses	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
for	for	O	O	O	O
an	an	O	O	O	O
overall	overall	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
16	16	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Most	most	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
57	57	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
stopped	stopped	O	O	O	O
treatment	treatment	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
disease	disease	O	DISEASE	OTHERS	I
progression	progression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Neurologic	neurologic	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
was	was	O	O	O	O
reported	reported	O	O	O	O
in	in	O	O	O	O
52	52	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Seven	seven	O	O	O	O
different	different	O	O	O	O
life-threatening	life-threatening	O	O	O	O
toxicities	toxicities	O	DISEASE	OTHERS	I
were	were	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
while	while	O	O	O	O
receiving	receiving	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
amifostine	amifostine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
an	an	O	O	O	O
overall	overall	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
16	16	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Neither	neither	O	O	O	O
a	a	O	O	O	O
tumor-protective	tumor-protective	O	O	O	O
effect	effect	O	O	O	O
nor	nor	O	O	O	O
reduced	reduced	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
to	to	O	O	O	O
normal	normal	O	O	O	O
tissues	tissues	O	O	O	O
was	was	O	O	O	O
observed	observed	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
addition	addition	O	O	O	O
of	of	O	O	O	O
amifostine	amifostine	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
cisplatin	cisplatin	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
this	this	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

